Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosareceiving vitamin a treatment
EL Berson, B Rosner, MA Sandberg… - Archives of …, 2004 - jamanetwork.com
Objective To determine whether a therapeutic dose of docosahexaenoic acid (DHA), an ω-3
fatty acid, will slow the course of retinal degeneration in adultpatients with retinitis
pigmentosa who are also receiving vitamin A. Design Randomized, controlled, double-
masked trial of 221 patients, aged 18to 55 years, evaluated over a 4-year interval. Patients
were given either1200 mg/d of docosahexaenoic acid or control capsules. All were given 15
000IU/d of vitamin A (given as retinyl palmitate). Randomization considered genetictype and …
fatty acid, will slow the course of retinal degeneration in adultpatients with retinitis
pigmentosa who are also receiving vitamin A. Design Randomized, controlled, double-
masked trial of 221 patients, aged 18to 55 years, evaluated over a 4-year interval. Patients
were given either1200 mg/d of docosahexaenoic acid or control capsules. All were given 15
000IU/d of vitamin A (given as retinyl palmitate). Randomization considered genetictype and …
